



# ICLG

The International Comparative Legal Guide to:

## Pharmaceutical Advertising 2015

**12th Edition**

A practical cross-border insight into pharmaceutical advertising

Published by Global Legal Group, with contributions from:

A. Lopes Muniz Advogados Associados

Adams & Adams

Advokatfirmaet Grette DA

Arnold & Porter (UK) LLP

Arthur Cox

Biolato Longo Ridola & Mori

Boga & Associates

Clayton Utz

Clifford Chance

CMS

Debarliev, Dameski & Kelesoska Attorneys at Law

DLA Piper (Canada) LLP

Faus & Moliner

Gün + Partners

Herbst Kinsky Rechtsanwälte GmbH

Hwang Mok Park P.C.

Jones Day

Jusmedico Advokatanpartsselskab

Locke Lord LLP

Life Sciences Legal | Niche law firm

Mannheimer Swartling Advokatbyrå

Nishimura & Asahi

OLIVARES

Pestalozzi Attorneys at Law

Roschier, Attorneys Ltd.

Sołtysiński Kawecki & Szlęzak

Subramaniam & Associates (SNA)

Tilleke & Gibbins

Van Innis & Delarue

Vieira de Almeida & Associados

**GLG**

Global Legal Group

**Contributing Editor**  
Ian Dodds-Smith, Arnold & Porter (UK) LLP

**Head of Business Development**  
Dror Levy

**Sales Director**  
Florjan Osmani

**Commercial Director**  
Antony Dine

**Account Directors**  
Oliver Smith, Rory Smith

**Senior Account Manager**  
Maria Lopez

**Sales Support Manager**  
Toni Hayward

**Editor**  
Gemma Bridge

**Senior Editor**  
Suzie Levy

**Group Consulting Editor**  
Alan Falach

**Group Publisher**  
Richard Firth

**Published by**  
Global Legal Group Ltd.  
59 Tanner Street  
London SE1 3PL, UK  
Tel: +44 20 7367 0720  
Fax: +44 20 7407 5255  
Email: info@glgroup.co.uk  
URL: www.glgroup.co.uk

**GLG Cover Design**  
F&F Studio Design

**GLG Cover Image Source**  
iStockphoto

**Printed by**  
Information Press Ltd.  
June 2015

Copyright © 2015  
Global Legal Group Ltd.  
All rights reserved  
No photocopying

ISBN 978-1-910083-49-9  
ISSN 1743-3363

**Strategic Partners**



**General Chapter:**

1	<b>Legal Issues Arising from the Marketing and Promotion of Companion Diagnostics in the EU</b> – Adela Williams & Silvia Valverde, Arnold & Porter (UK) LLP	1
---	---	---

**Country Question and Answer Chapters:**

2	<b>Albania</b>	Boga & Associates: Renata Leka & Elona Xhepa	6
3	<b>Australia</b>	Clayton Utz: Colin Loveday & Greg Williams	13
4	<b>Austria</b>	Herbst Kinsky Rechtsanwälte GmbH: Dr. Sonja Hebenstreit & Dr. Isabel Funk-Leisch	25
5	<b>Belgium</b>	Van Innis & Delarue: Dieter Delarue & Anthony Van der Planken	37
6	<b>Brazil</b>	A. Lopes Muniz Advogados Associados: Marcos Lobo de Freitas Levy & Mariana Carneiro Lopes Muniz	48
7	<b>Bulgaria</b>	CMS Bulgaria: David Butts & Angelika Dimitrova	56
8	<b>Canada</b>	DLA Piper (Canada) LLP: Bill Hearn & Sara Zborovski	67
9	<b>China</b>	Jones Day: Chiang Ling Li & Haifeng Huang	83
10	<b>Czech Republic</b>	CMS Czech Republic: Tomáš Matějovský & Barbora Dubanská	93
11	<b>Denmark</b>	Jusmedico Advokatanpartsselskab: Jan Bjerrum Bach & Lone Hertz	101
12	<b>England &amp; Wales</b>	Arnold & Porter (UK) LLP: Silvia Valverde & Jackie Mulryne	116
13	<b>Finland</b>	Roschier, Attorneys Ltd.: Mikael Segercrantz & Johanna Lilja	130
14	<b>Germany</b>	Clifford Chance: Dr. Peter Dieners & Jan Szemjonneck	141
15	<b>Hungary</b>	CMS Hungary: Dóra Petrányi & Miriam Fuchs	154
16	<b>India</b>	Subramaniam & Associates (SNA): Hari Subramaniam & Aditi Subramaniam	164
17	<b>Ireland</b>	Arthur Cox: Colin Kavanagh & Rory O'Connor	174
18	<b>Italy</b>	Biolato Longo Ridola & Mori: Linda Longo & Michela Merella	185
19	<b>Japan</b>	Nishimura & Asahi: Somuku Iimura & Yoko Kasai	197
20	<b>Korea</b>	Hwang Mok Park P.C.: Hye Yeon Lim & Jong Bae Shin	206
21	<b>Kosovo</b>	Boga & Associates: Besarta Kllokoqi & Delvina Nallbani	214
22	<b>Macedonia</b>	Debarliev, Dameski & Kelesoska Attorneys at Law: Emilija Kelesoska Sholjakovska	222
23	<b>Mexico</b>	OLIVARES: Alejandro Luna Fandiño & Erwin Cruz	229
24	<b>Netherlands</b>	Life Sciences Legal   Niche law firm: <i>mr. ir.</i> Anke E. Heezius	240
25	<b>Norway</b>	Advokatfirmaet Grette DA: Felix Reimers & Håkon Austdal	248
26	<b>Poland</b>	Sołtysiński Kawecki & Szlęzak: Dr. Ewa Skrzydło-Tefelska & Katarzyna Bieliszczuk	259
27	<b>Portugal</b>	Vieira de Almeida & Associados: Paulo Pinheiro & Francisca Paulouro	267
28	<b>Romania</b>	CMS Romania: Valentina Parvu & Ioana Barbu	277
29	<b>Russia</b>	CMS Russia: Vsevolod Tyupa	290
30	<b>South Africa</b>	Adams & Adams: Alexis Apostolidis & Pieter Visagie	298
31	<b>Spain</b>	Faus & Moliner: Jordi Faus & Carmela Losada	308
32	<b>Sweden</b>	Mannheimer Swartling Advokatbyrå: Helén Waxberg & Jenny Bergström	319
33	<b>Switzerland</b>	Pestalozzi Attorneys at Law: Dr. Lorenza Ferrari Hofer & Lukas Herforth	329
34	<b>Turkey</b>	Gün + Partners: Özge Atılğan Karakulak & Ceren Aral	337
35	<b>USA</b>	Locke Lord LLP: Sharon Blinkoff & Kayla Tabela	347
36	<b>Vietnam</b>	Tilleke & Gibbins: Kien Trung Trinh & Tu Ngoc Trinh	356

Further copies of this book and others in the series can be ordered from the publisher. Please call +44 20 7367 0720

**Disclaimer**

This publication is for general information purposes only. It does not purport to provide comprehensive full legal or other advice. Global Legal Group Ltd. and the contributors accept no responsibility for losses that may arise from reliance upon information contained in this publication. This publication is intended to give an indication of legal issues upon which you may need advice. Full legal advice should be taken from a qualified professional when dealing with specific situations.

# Portugal

Paulo Pinheiro



Francisca Paulouro



Vieira de Almeida & Associados

## 1 General – Medicinal Products

### 1.1 What laws and codes of practice govern the advertising of medicinal products in Portugal?

The advertising of medicinal products in Portugal is governed by Decree-Law 176/2006, of the 30th of August 2006, as amended (“Medicines Code”), which transposed into the Portuguese legal system Directive 2001/83/EC, of the 6th of November 2001, on the Community Code relating to medicinal products for human use, as amended (“Directive”).

The regime set forth in the Medicines Code closely follows the regime provided for in the Directive, comprising a set of rules concerning, amongst others: (i) the definition of advertising; (ii) the requirements applicable to advertising to the general public; (iii) the requirements applicable to advertising to persons qualified to prescribe, dispense and administer medicinal products (healthcare professionals); (iv) the obligations of both the marketing authorisation (“MA”) holder and of the company responsible for the promotion; (v) the requirements related with the activity of the medical sales representatives when advertising a medicinal product; (vi) scientific and promotional events and accommodation costs; and (vii) the terms and conditions subject to which the offer of free samples is permitted. The Medicines Code further establishes the supervision and sanctioning powers of the Portuguese Agency, INFARMED.

In addition, Decree-Law 330/90, of the 23rd of October 1990, as amended (“Advertising Code”), which establishes the rules applicable to advertising in general, is applicable to the advertising of medicinal products in all matters not specifically provided for in the Medicines Code.

Finally, Resolution 044/CD/2008, of the 7th February 2008, issued by INFARMED and which came into force on the 1st of April 2008, approved the “Advertising Regulation” which specifies certain aspects related to the advertising of medicinal products, such as: (i) the particulars which must be included in advertising to healthcare professionals (“HCPs”), defining what is essential information compatible with the summary of the product’s characteristics (“SmPC”); (ii) the number of samples that may be distributed to physicians per year; and (iii) the submission of advertising materials to INFARMED.

At a deontological level, the APIFARMA Code of Practice for the Pharmaceutical Industry (“APIFARMA Code”) and the APIFARMA Code on relationships between the Pharmaceutical

Industry and Patient Organisations (“APIFARMA Code on Patient Organisations”), both approved by the Association of the Portuguese Pharmaceutical Industry (“APIFARMA”), a member of the European Federation of Pharmaceutical Industries and Associations (“EFPIA”), must also be considered. The APIFARMA Code, which implements the EFPIA Code, reinstates and, in some cases, furthers, the rules foreseen in the Medicines Code. The APIFARMA Code and the APIFARMA Code on Patient Organisations apply only to member companies of APIFARMA.

In parallel, other rules must be taken into account, particularly in what concerns the protection of confidential information and unfair commercial practices. For this purpose Decree-Law 36/2003, of the 5th of March 2003, as amended (“Industrial Property Code”) and Decree-Law 57/2008, of the 26th of March 2008, transposing Directive 2005/29/CE (“Unfair Commercial Practices Code”), may be deemed applicable depending on the issues at stake.

### 1.2 How is “advertising” defined?

Advertising is defined in the Medicines Code as any form of information, canvassing or incentive which has as its object or effect the promotion of the prescription, supply, sale, purchase or consumption of medicinal products, in any of the following situations:

- (a) to the general public;
- (b) to wholesale distributors and HCPs;
- (c) by means of visits by medical sales representatives to the persons referred to in (b) above;
- (d) through the supply of samples or the granting of commercial bonuses to any of the persons referred to in (b) above;
- (e) through the grant, offer or promise of benefits, whether in money or in kind, except if of an intrinsic insignificant value;
- (f) through the sponsorship of promotional or scientific events to be attended by the persons referred to in (b) above, such as, *via* the direct or indirect payment of accommodation costs; or
- (g) by reference to the commercial name of the medicinal product.

The advertising regime of the Medicines Code does not apply to:

- (a) the labelling and the accompanying package leaflet approved in accordance with the Medicines Code and the applicable European Law;
- (b) the correspondence needed to answer a specific question about a particular medicinal product, possibly accompanied by any document, as long as it does not contain any element of a promotional nature;

- (c) factual, informative announcements and reference material relating to packaging changes, adverse reaction warnings in what concerns pharmacovigilance, trade catalogues and price lists, provided they do not include any other information regarding the medicinal product;
- (d) information regarding human health or diseases provided that there is no reference, even indirectly, to a medicinal product; and
- (e) measures or commercial practices in regard to margins, prices and discounts.

---

**1.3 What arrangements are companies required to have in place to ensure compliance with the various laws and codes of practice on advertising, such as “sign off” of promotional copy requirements?**

---

The MA holder must create and maintain a scientific service in charge of the information about the medicinal products it places on the market.

The MA holder is further obliged to, namely through the abovementioned scientific service, amongst others: (i) keep complete and detailed records of the advertisement made by the company in documents that mention the recipients, the means and the dates of the first disclosure; (ii) maintain these records and make them available to INFARMED for a minimum period of five years, counted from the date of the first disclosure; (iii) guarantee that the advertising undertaken by its company or on behalf of its company respects the requirements set forth by applicable laws; (iv) ensure that medical sales representatives have the adequate qualifications and the necessary training to carry out their responsibilities in full respect of their obligations and applicable laws; and (v) cooperate with the competent public authorities, particularly by providing information and necessary assistance in what concerns the monitoring of advertising.

Furthermore, and subject to what is provided for in the Advertising Regulation, the MA holder must send INFARMED a summary description of any advertising material regarding medicinal products within 10 days counting from its first disclosure.

---

**1.4 Are there any legal or code requirements for companies to have specific standard operating procedures (SOPs) governing advertising activities? If so, what aspects should those SOPs cover?**

---

There are no legal or deontological requirements establishing that companies must have SOPs governing their promotional activities.

Nevertheless, several pharmaceutical companies operating in Portugal have developed and implemented SOPs, which aim at ensuring the consistency of the respective advertising activities with the applicable legal and deontological framework.

---

**1.5 Must advertising be approved in advance by a regulatory or industry authority before use? If so, what is the procedure for approval? Even if there is no requirement for prior approval in all cases, can the authorities require this in some circumstances?**

---

Advertising does not need to be previously approved by INFARMED or by any other regulatory or industry authority.

However, the Advertising Regulation establishes that the MA holder must send INFARMED a summary description of each advertising

material. Note that INFARMED may, at all times, require a copy of the material. This procedure consists of a notification to INFARMED through the submission of a form available at its website, within 10 days from the first disclosure of the advertising material at stake.

As an alternative to the above, the MA holder may submit a summary description of each advertising material included in an advertising campaign or in an annual plan of advertising events.

---

**1.6 If the authorities consider that an advertisement which has been issued is in breach of the law and/or code of practice, do they have powers to stop the further publication of that advertisement? Can they insist on the issue of a corrective statement? Are there any rights of appeal?**

---

When INFARMED considers that a company is in breach of the laws regarding advertising of medicinal products, it may initiate a misdemeanour procedure – the infringement of advertisement rules being considered misdemeanours.

If in the context of such procedure it is found that a breach in fact occurred, INFARMED may apply a fine and order the company to stop further disclosure of the advertising materials. Ancillary sanctions may also be applied by INFARMED. INFARMED’s decision is subject to appeal to the judicial courts. If, on the contrary, what is at stake is an infringement of the APIFARMA Code, the disciplinary powers belong to APIFARMA, which may initiate a disciplinary procedure against the member company concerned. In case APIFARMA finds that a breach did take place, it may request the company to immediately stop the advertising and undertake not to repeat the violation. APIFARMA may also apply sanctions which include: (i) a warning; (ii) a pecuniary fine; or (iii) the suspension of the membership of the company from the association for a specific period of time or even the company’s expulsion.

---

**1.7 What are the penalties for failing to comply with the rules governing the advertising of medicines? Who has responsibility for enforcement and how strictly are the rules enforced? Are there any important examples where action has been taken against pharmaceutical companies? To what extent may competitors take direct action through the courts?**

---

The infringement of the rules provided for in the Medicines Code regarding advertising constitutes a misdemeanour, which is punishable by a fine that can range from €2,000 to 15% of the responsible person’s turnover, or to €180,000, whichever is the lowest. The applicable penalties in case of breach of the rules concerning (i) the medical sales representative’s access to the National Health Service (“NHS”) hospitals, and (ii) free samples are also punished with fines which can range from €2,000 to 10% of the responsible person’s turnover, or to €120,000, whichever is the lowest.

Note that the advertising agency, or any other entity that is involved in the advertising activity, is also punished as an author or co-author of the referred regulatory offences for the breach of the rules governing the advertising.

Furthermore, ancillary sanctions may be applied, such as the publication in the media, at the expense of the company, of the essential elements that determined the conviction, the suspension of the advertising activity of the product for a period of up to two years and the prohibition from participating in public tenders also for up to two years.



Moreover, reimbursed medicines may be de-listed as a consequence of infringement of advertising rules. The process for de-listing is autonomous from the misdemeanour procedure and may run in parallel.

INFARMED is the entity which has the responsibility for enforcing the rules applicable to the advertising of medicines.

A misdemeanour procedure with the aim of applying a fine as a result of the disrespect of advertising rules is initiated and decided by INFARMED, even if on the basis of a complaint submitted to it by competitors. Therefore, competitors may not take direct action through the courts in what concerns the misdemeanour procedure. However, in general terms, the misdemeanour procedure does not exclude the potential civil liability of the company, which competitors may bring to court by filing a civil liability lawsuit.

---

**1.8 What is the relationship between any self-regulatory process and the supervisory and enforcement function of the competent authorities? Can, and, in practice, do, the competent authorities investigate matters drawn to their attention that may constitute a breach of both the law and any relevant code and are already being assessed by any self-regulatory body? Do the authorities take up matters based on an adverse finding of any self-regulatory body?**

---

There is no relation between the supervisory and enforcement powers of INFARMED and the self-regulatory processes within APIFARMA.

INFARMED is solely competent for enforcing the advertising rules provided for in the Medicines Code, whereas a breach of the rules established in the APIFARMA Code is exclusively the competence of APIFARMA.

---

**1.9 In addition to any action based specifically upon the rules relating to advertising, what actions, if any, can be taken on the basis of unfair competition? Who may bring such an action?**

---

In addition to any action based specifically upon the rules relating to advertising, a company that was harmed by an advertisement may also react through a lawsuit based on unfair competition or on the infringement of the rules regarding protection of confidential information which are set forth by the Industrial Property Code, both considered misdemeanours and punishable with fines that may range from €3,000 to €30,000.

Additionally, another action that may be taken against advertisement may be based on the Unfair Commercial Practices Code. Consumers and competitors negatively affected by advertisement considered an unfair commercial practice may take legal action in order to prevent, correct or stop such practice. Unfair commercial practices may also be sanctioned within misdemeanour procedures that may be initiated either by INFARMED or by the Consumer's Government Department. Fines may range from €3,000 to €44,891.81.

---

**2 Providing Information Prior to Authorisation of Medicinal Product**

---

**2.1 To what extent is it possible to make information available to healthcare professionals about a medicine before that product is authorised? For example, may information on such medicines be discussed, or made available, at scientific meetings? Does it make a difference if the meeting is sponsored by the company responsible for the product? Is the position the same with regard to the provision of off-label information (i.e. information relating to indications and/or other product variants not authorised)?**

---

The advertisement of medicinal products that do not have a valid market authorisation or registration in Portugal, or that have been authorised under special or exceptional authorisations, is not permitted. It is only possible to make information available to HCPs regarding unauthorised medicinal products if it does not qualify as advertising and therefore does not constitute an incentive to the prescription or purchase of the medicinal product.

Said information may be made available at meetings of a scientific nature, whether sponsored by the company responsible for the product or a third entity. In any case, when the company responsible for the product is also sponsoring the meeting, there is an increased risk of the information being considered as advertising.

The provision of off-label information is only admissible as long as it may not in any way be considered promotion. In essence, the rule for off-label is the same as for non-authorised products – in both cases we are dealing with unauthorised products/indications.

---

**2.2 May information on unauthorised medicines and/or off-label information be published? If so, in what circumstances?**

---

Information on unauthorised medicines may only be published if such information is not considered advertising, and hence does not have as its purpose or effect the promotion of the prescription, supply, sale, purchase or consumption of the product, and if the same is of a scientific and objective nature. The same applies to off-label information.

---

**2.3 Is it possible for companies to issue press releases about unauthorised medicines and/or off-label information? If so, what limitations apply?**

---

Press releases on unauthorised medicines and/or off-label information may only be issued if such press releases are not considered advertising and have a scientific nature. Thus, such press releases may be issued to the extent they do not have as their purpose or effect the promotion of the prescription, supply, sale, purchase or consumption of the product – and therefore cannot in any way be considered advertising. When such press releases are issued by the pharmaceutical company, they should only contain information regarding human health and diseases.

#### 2.4 May such information be sent to healthcare professionals by the company? If so, must the healthcare professional request the information?

The company may send such information to HCPs, upon their request, and it may be accompanied by documentation as long as it does not contain any advertising elements. In such case the company is addressing a specific question put forward by the HCP and not acting proactively.

#### 2.5 How has the ECJ judgment in the *Ludwigs* case, Case C-143/06, permitting manufacturers of non-approved medicinal products (i.e. products without a marketing authorisation) to make available to pharmacists price lists for such products (for named-patient/compassionate use purposes pursuant to Article 5 of the Directive), without this being treated as illegal advertising, been reflected in the legislation or practical guidance in Portugal?

The ECJ judgment in the *Ludwigs* case regarding non-approved medicinal products has not been directly reflected in the legislation or practical guidance in Portugal.

In regard to price lists of approved medicinal products made available to pharmacists, the Medicines Code does not consider them as advertising and, consequently, the rules on advertising are not applicable to them. The Advertising Regulation clarifies what should be understood by price lists, providing that these should be identified as such and contain only the name, composition, dosage, pharmaceutical form, package size and price of the medicinal products. Price lists do not need to be notified to INFARMED.

#### 2.6 May information on unauthorised medicines or indications be sent to institutions to enable them to plan ahead in their budgets for products to be authorised in the future?

Companies may only send information to institutions provided that it is necessary to answer a specific question regarding a certain medicinal product.

#### 2.7 Is it possible for companies to involve healthcare professionals in market research exercises concerning possible launch materials for medicinal products as yet unauthorised? If so, what limitations apply? Has any guideline been issued on market research of medicinal products?

Companies may involve HCPs in market research exercises concerning unauthorised medicinal products under a services agreement. No specific guidelines have been issued in this respect.

### 3 Advertisements to Healthcare Professionals

#### 3.1 What information must appear in advertisements directed to healthcare professionals?

Advertising to HCPs must include:

- (a) the name of the medicinal product;

- (b) essential information compatible with the SmPC, which comprises the following information: (i) the name; (ii) the qualitative and quantitative composition; (iii) the pharmaceutical form; (iv) the therapeutic indications; (v) the posology and method of administration; and (vi) the contraindications and adverse reactions of the medicinal product. If relevant from a clinical point of view, the following additional information must also be included: (i) warnings and special precautions for use; and (ii) interactions with other medicinal products and other forms of interaction;
- (c) the classification of the medicinal product for dispensing purposes; and
- (d) the reimbursement regime.

The above information is not required when the advertisement consists of a name reminder of the name of the medicinal product. For a material to be considered as a name reminder, it cannot include any indications other than (i) the name, the active substance, the strength and the pharmaceutical form of the medicinal product, and (ii) the identification of the MA or registry holder.

#### 3.2 Are there any restrictions on the information that may appear in an advertisement? May an advertisement refer to studies not mentioned in the SmPC?

Although the ECJ judgment in Case C-249/09 was not formally implemented in Portuguese legislation or guidance, advertisements, besides not being misleading, must be in accordance with the SmPC, but do not have to reproduce it. Moreover, quotations, as well as illustrative matter taken from medical journals or other scientific works for use in the documentation, must be correctly reproduced and the respective source indicated. An advertisement may refer to studies not in the SmPC, provided that such studies are in accordance therewith.

#### 3.3 Are there any restrictions to the inclusion of endorsements by healthcare professionals in promotional materials?

There are no restrictions to the inclusion of endorsements by HCPs in promotional materials addressed exclusively to such professionals provided that all legal requirements are fulfilled and that such endorsements are accurate, current, verifiable and sufficiently complete. It is, however, prohibited to include any kind of endorsements by HCPs in promotional materials directed to the general public.

#### 3.4 Is it a requirement that there be data from any, or a particular number of, "head to head" clinical trials before comparative claims may be made?

There is no specific legal requirement regarding the number of "head to head" clinical trials that should exist for comparative claims to be made. In any event, the legal regime applicable to comparative advertising requires that the comparative claims be verifiable.

---

### 3.5 What rules govern comparative advertisements? Is it possible to use another company's brand name as part of that comparison? Would it be possible to refer to a competitor's product which had not yet been authorised in Portugal?

---

According to the Medicines Code, comparative advertising is only allowed if directed to HCPs. In this case, the regime of the Advertising Code applies.

Under the Advertising Code, comparative advertising (i) must not be misleading, and (ii) must objectively compare one or more of the essential, relevant, verifiable and representative characteristics of the medicinal products. According to said regime, it is possible to use another company's brand name as part of the comparison provided that it does not create confusion in the market between the brand names and does not discredit/denigrate the brand name, or take unfair advantage of its reputation.

Further to these requirements, the Medicines Code establishes that the information contained in documentation provided to the HCPs must be accurate, current, verifiable and sufficiently complete to enable the recipient to make a correct idea of the therapeutic value of the medicine.

Additionally, the APIFARMA Code provides that comparisons between medicinal products (i) should be based on relevant and comparable aspects, (ii) should neither be misleading nor defamatory, and (iii) should only be made based on the elements included in the respective SmPC or on credible clinical data.

There is no specific regime concerning the possibility of referring to a competitor's product which has not yet been authorised. However, the Advertising Code requires that the advertising compares products that respond to the same needs or have the same purposes. As such, if the product is not authorised such requirement is not fulfilled.

---

### 3.6 What rules govern the distribution of scientific papers and/or proceedings of congresses to healthcare professionals?

---

The APIFARMA Code sets out that informative or instructive material may be distributed to HCPs as long as these are of low monetary value, as well as relevant to their professional activity, and directly benefit the performance of healthcare to patients.

Also, if these papers qualify as advertising (e.g. identifying a given product), the requirements established in the Medicines Code concerning advertising of medicinal products before HCPs, in particular the requirements mentioned in question 3.1, apply. It should further be noted that the Medicines Code requires that the documents handed over to HCPs include an indication of the date when they were established and last reviewed. The information contained therein must be accurate, current, verifiable and sufficient to allow the recipient to make a correct idea of the therapeutic value of the medicine.

---

### 3.7 Are "teaser" advertisements permitted that alert a reader to the fact that information on something new will follow (without specifying the nature of what will follow)?

---

There is no specific regime regarding "teaser" advertisements. However, if a teaser identifies a given medicine, it must always contain the minimum information mentioned in question 3.1 if addressed to HCPs.

---

## 4 Gifts and Financial Incentives

---

### 4.1 Is it possible to provide healthcare professionals with samples of medicinal products? If so, what restrictions apply?

---

Free samples may only be provided to physicians, on an exceptional basis, if:

- they do not exceed the number of units foreseen, per year, per HCPs (four units, in accordance with the APIFARMA Code, and 12 units, in accordance with the Medicines Code);
- they are in response to a written request, signed and dated, from the prescribing agent;
- they are not larger than the smallest presentation on the market;
- each sample is marked "Free sample" or "Not for sale", or contains a similar warning; and
- they are accompanied by a copy of the SmPC.

Free samples of prescription-only products may only be supplied during the two years following the date of their effective marketing.

Samples of products containing narcotics or psychotropic substances are prohibited.

Companies are obliged to create an adequate system of control and accountability of samples, which shall be kept at the disposal of the supervisory authorities, for a period of five years.

---

### 4.2 Is it possible to give gifts or donations of money to healthcare professionals? If so, what restrictions apply?

---

Under the Medicines Code, the holder of a MA, or the company responsible for the information or promotion of a medicinal product or the wholesale distributor, may not offer or promise to offer, directly or indirectly, to HCPs gifts, bonuses or pecuniary advantages or benefits in kind, except when these are of insignificant value and relevant to the practice of medicine or pharmacy.

Subject to what is set forth in Order 12284/2014, of the 6th of October 2014, objects of "insignificant value" are those which the purchase cost does not exceed €60.

---

### 4.3 Is it possible to give gifts or donations of money to healthcare organisations such as hospitals? Is it possible to donate equipment, or to fund the cost of medical or technical services (such as the cost of a nurse, or the cost of laboratory analyses)? If so, what restrictions would apply?

---

It is possible to give gifts or donations of money to institutions, such as hospitals, as long as these are not directed to individual HCPs and do not constitute an inducement to purchase or administer specific medicines. The same applies to the donation of equipment and the funding of the costs of medical or technical services (such as the cost of a nurse or the cost of laboratory analyses). Such donations may, however, have implications under public procurement rules, should the recipient be a public entity.

According to the APIFARMA Code, these gifts, donations or funding should be documented in a written agreement and must be subsequent to a written request from the beneficiary.

**4.4 Is it possible to provide medical or educational goods and services to healthcare professionals that could lead to changes in prescribing patterns? For example, would there be any objection to the provision of such goods or services if they could lead either to the expansion of the market for, or an increased market share for, the products of the provider of the goods or services?**

Gifts, donations or pecuniary advantages or benefits in kind to HCPs are only possible under the terms described in question 4.2, provided that they do not lead to changes in prescribing patterns. It is possible to sponsor promotional meetings or scientific congresses attended by HCPs, including payment of travel and accommodation costs in connection therewith. Any other advantage, including medical or educational goods and services, provided to HCPs is forbidden. It is possible, however, to compensate HCPs for services rendered under, and specified in, a services agreement.

**4.5 Do the rules on advertising and inducements permit the offer of a volume-related discount to institutions purchasing medicinal products? If so, what types of arrangements are permitted?**

Commercial measures or practices with regard to margins, prices and discounts are not considered advertising. Any limitations in this respect are those potentially arising from pricing, competition and public procurement rules.

**4.6 Is it possible to offer to provide, or to pay for, additional medical or technical services or equipment where this is contingent on the purchase of medicinal products? If so, what conditions would need to be observed?**

No. Refer to the answers to questions 4.2, 4.3 and 4.4 above.

**4.7 Is it possible to offer a refund scheme if the product does not work? If so, what conditions would need to be observed? Does it make a difference whether the product is a prescription-only medicine, or an over-the-counter medicine?**

Refunding schemes if the product does not work are not expressly foreseen in Portuguese law. However, rules on reimbursement and access of hospital products to hospitals within the NHS establish the possibility of a contract being entered into between the MA holder and INFARMED, providing that the MA holder must reimburse the NHS should the sales of the product exceed a predetermined threshold.

**4.8 May pharmaceutical companies sponsor continuing medical education? If so, what rules apply?**

Pharmaceutical companies may only sponsor continuing medical education through the sponsoring of scientific congresses (including payment of travel and accommodation costs in relation therewith). Any other initiative would fall under the prohibition of making offers or donations to healthcare professionals (as it is not of an insignificant value) and would thus not be permitted.

## 5 Hospitality and Related Payments

**5.1 What rules govern the offering of hospitality to healthcare professionals? Does it make a difference if the hospitality offered to those healthcare professionals will take place in another country? Is there a threshold applicable to the costs of hospitality or meals provided to a healthcare professional?**

The Medicines Code and the APIFARMA Code provide the following rules:

- the companies responsible for the sponsorship or organisation of promotional or scientific/professional events may only bear the hospitality costs of the respective participants and those costs which are limited to the main objective of said event;
- hospitality costs only include those related to the enrolment, travel and accommodation of HCPs attending the abovementioned events;
- hospitality costs may not exceed the period between the day before the beginning of the event and the day after its conclusion and may not include any other social programme or activity which may hinder or prevent a full participation in the event; and
- the choice of the location of the event should follow professional and logistical criteria and involve, particularly with regard to hospitality, financial costs appropriate to the purpose intended.

Regarding hospitality costs of events taking place in other countries, the APIFARMA Code provides that these can only be organised or sponsored if:

- the majority of the participants are foreigners and, taking into account the home countries of most of the guests, it is more reasonable, in logistic terms, to carry out the event in another country; or
- taking into account the location of the resources or relevant knowledge which is the object or topic of the event, it is more reasonable, in logistic terms, to carry out the event in another country.

Also, the threshold for the cost of meals provided to HCPs is set in the APIFARMA Code at €60 for events taking place in Portugal and €90 for events abroad, unless the local regulations set different limits – in which case the latter apply.

**5.2 Is it possible to pay for a healthcare professional in connection with attending a scientific meeting? If so, what may be paid for? Is it possible to pay for his expenses (travel, accommodation, enrolment fees)? Is it possible to pay him for his time?**

The payment of fees for the active participation of HCPs in training, promotional or scientific events is allowed, provided that said payment is not dependent on, or constitutes an incentive to, the prescription or supply of medicines.

Expenses with travel, accommodation and enrolment fees may also be borne under the terms referred to in question 5.1.

Time spent by HCPs in attending scientific events cannot be paid.



**5.3 To what extent will a pharmaceutical company be held responsible by the regulatory authorities for the contents of, and the hospitality arrangements for, scientific meetings, either meetings directly sponsored or organised by the company or independent meetings in respect of which a pharmaceutical company may provide sponsorship to individual healthcare professionals to attend?**

Pharmaceutical companies may be held responsible by INFARMED for the infringement of the rules provided for in the Medicines Code regarding scientific events and hospitality costs. Infringement of said rules by a pharmaceutical company constitutes a misdemeanour sanctioned with a fine. Please refer to question 1.7.

**5.4 Is it possible to pay healthcare professionals to provide expert services (e.g. participating in advisory boards)? If so, what restrictions apply?**

It is possible to pay HCPs to provide expert services as long as the payment does not constitute an incentive for the prescription or purchase of medicines. According to the APIFARMA Code, said services must be ruled by a written agreement.

**5.5 Is it possible to pay healthcare professionals to take part in post-marketing surveillance studies? What rules govern such studies?**

The payment of HCPs for their participation in post-marketing surveillance studies is permitted provided that it does not constitute an incentive for the prescription or the purchase of medicines. Participation of HCPs in these activities should also not involve the collection and processing of prescribing data. These studies are governed by Law 21/2014, of the 16th of April (“Clinical Research Law”), which approved the regime applicable to Clinical Research, non-interventional studies included.

**5.6 Is it possible to pay healthcare professionals to take part in market research involving promotional materials?**

The payment of HCPs for their participation in market research involving promotional materials is allowed, with the limitations provided for in question 5.5 above.

## 6 Advertising to the General Public

**6.1 Is it possible to advertise non-prescription medicines to the general public? If so, what restrictions apply?**

It is possible to advertise non-prescription medicines to the general public if they are not reimbursed by the NHS. In this case, advertising must be set out in such a way that it is clear that the message is an advertisement and that the product is a medicinal product, and must include the following information:

- (a) the name of the medicinal product, as well as the common name if the medicinal product contains only one active substance, or its brand name;
- (b) the information necessary for the correct use of the medicinal product, including therapeutic indications and special precautions; and

- (c) an invitation to the consumer to carefully read the information on the outer packaging and on the package leaflet and, in case of doubt or persistence of the symptoms, to consult a doctor or pharmacist.

The advertising of medicinal products to the general public may not contain any material which:

- (a) gives the impression that a medical consultation or a surgical operation is unnecessary, in particular by offering a diagnosis or by suggesting treatment by mail;
- (b) suggests that the effects of taking the medicine are guaranteed, unaccompanied by adverse reactions or better than, or equivalent to, those of another treatment or medicinal product;
- (c) suggests that his/her health can be enhanced by taking the medicine;
- (d) suggests that his/her health could be affected by not taking the medicine, except in what regards vaccination campaigns previously approved by INFARMED;
- (e) is directed exclusively or mainly at children;
- (f) refers to a recommendation by scientists, HCPs or persons who are neither of the foregoing but who, because of their celebrity, could encourage the consumption of medicinal products;
- (g) suggests that the medicinal product is a foodstuff, cosmetic or other consumer product;
- (h) suggests that the safety or efficacy of the medicinal product is due to the fact that it is natural;
- (i) could, by a description or detailed representation of a case history, lead to erroneous self-diagnosis;
- (j) refers, in improper, alarming or misleading terms, to claims of recovery; or
- (k) uses, in improper, alarming or misleading terms, pictorial representations of changes in the human body caused by disease or injury, or by the action of a medicinal product on the human body or parts thereof.

Any form of comparative advertising before the public is prohibited. Furthermore, the direct distribution of medicinal products for promotional purposes to the public, as well as the granting of any kind of benefit to the general public or to patients, are prohibited.

**6.2 Is it possible to advertise prescription-only medicines to the general public? If so, what restrictions apply?**

Advertising prescription-only medicines to the general public is not permitted.

**6.3 If it is not possible to advertise prescription-only medicines to the general public, are disease awareness campaigns permitted encouraging those with a particular medical condition to consult their doctor, but mentioning no medicines? What restrictions apply?**

Companies may provide information regarding human health and diseases, provided that no reference, even indirectly, is made to a medicinal product. Disease awareness campaigns are permitted under these terms.

#### 6.4 Is it possible to issue press releases concerning prescription-only medicines to non-scientific journals? If so, what conditions apply?

Press releases without promotional nature will not be considered advertising. As such, these may be published in non-scientific journals.

However, the promotional nature of a given piece of information must be assessed on a case-by-case basis. The lack of a link between the company and the journal is a factor to consider minimising the risk of the press release being considered as promotion.

#### 6.5 What restrictions apply to describing products and research initiatives as background information in corporate brochures/Annual Reports?

There are no specific rules in the Medicines Code regarding this matter. However, the APIFARMA Code allows companies to disclose institutional information, such as financial data, descriptions of R&D programmes and the analysis of legislative developments, which may affect the company and its products.

#### 6.6 What, if any, rules apply to meetings with, and the funding of, patient organisations?

The Medicines Code does not establish any specific rules regarding meetings and funding of patient organisations, other than those related with transparency requirements. Should these meetings consist of advertising of medicinal products, then the rules and limitations applicable in this regard, depending on the nature of the recipient (general public or HCPs), must be considered.

In what transparency requirements are concerned, pharmaceutical companies have to report to INFARMED the granting of any subsidy, sponsorship, subvention or any other value, good or right which may be evaluated in money, to an association or any other entity, regardless of its nature or form, representative of a patient organisation. This same obligation exists for the recipient of the benefit. The APIFARMA Code on Patient Organisations contains certain rules regarding the relationship with patient organisations. Amongst such rules, there are transparency requirements as regards the recording of donations and other financing support.

### 7 Transparency and Disclosure

#### 7.1 Is there an obligation for companies to disclose details of ongoing and/or completed clinical trials? If so, is this obligation set out in the legislation or in a self-regulatory code of practice? What information should be disclosed, and when and how?

The Clinical Research Law sets forth an obligation for companies sponsoring clinical trials to disclose details of the clinical trials, prior to their initiation, as well as any updates.

Such information should be included in a specific registry (“*Registo Nacional de Estudos Clínicos*”), which is not yet active, and is to be implemented by INFARMED.

Amongst other information, this registry shall include: (a) details regarding the clinical trial authorisation request and any amendments thereto; (b) information regarding the opinion of the Ethics Committee; (c) amendments to the Protocol; and (d) data related to suspicions of serious adverse events.

#### 7.2 Is there a requirement in the legislation for companies to make publicly available information about transfers of value provided by them to healthcare professionals, healthcare organisations or patient organisations? If so, what companies are affected, what information should be disclosed, from what date and how?

The Medicines Code establishes a general obligation for companies to report to INFARMED payments made to third parties, above €60.00, regardless of the nature of the recipient, including, amongst others, patient organisations, healthcare organisations and HCPs. Reporting should be done at INFARMED’s website within 30 days from payment. Companies must indicate the total amount paid for, its nature, and the name of the recipient. This information is publicly available at INFARMED’s website.

#### 7.3 Is there a requirement in your self-regulatory code for companies to make publicly available information about transfers of value provided by them to healthcare professionals, healthcare organisations or patient organisations? If so, what companies are affected, what information should be disclosed, from what date and how? Are companies obliged to disclose via a central platform?

Compliance with the legal reporting obligation mentioned in question 7.2 has been incorporated in the APIFARMA Code.

### 8 The Internet

#### 8.1 How is Internet advertising regulated? What rules apply? How successfully has this been controlled?

There is no specific regime regarding the advertising of medicinal products through the internet. In case the company owner of the website and the recipient of the information are both in the Portuguese territory, the rules concerning advertising to HCPs or the public in general provided for in the Medicines Code will apply.

The APIFARMA Code further provides that advertising of medicinal products to HCPs through the internet should be based on technical, scientific and professional principles and that companies should adopt measures to guarantee that such advertising is accessed only by them.

#### 8.2 What, if any, level of website security is required to ensure that members of the general public do not have access to sites intended for healthcare professionals?

There are no specific rules regarding website security. In any event, companies should ensure that advertising to HCPs made through the internet is only accessed by them – an obligation which is expressly provided for in the APIFARMA Code.

**8.3 What rules apply to the content of independent websites that may be accessed by a link from a company-sponsored site? What rules apply to the reverse linking of independent websites to a company's website? Will the company be held responsible for the content of the independent site in either case?**

The company owner of a website should always respect the rules applicable to the advertising of medicinal products. When the company has in its website a link to an independent website, a warning usually appears stating that the user is leaving the company's website. The same happens in the case of reverse linking of independent websites to the company's website. The company that has in its website a link to an independent website should not, in principle, be held responsible for the contents of the independent site in either case.

**8.4 What information may a pharmaceutical company place on its website that may be accessed by members of the public?**

Companies may place on their websites information concerning non-prescription medicines (if the same are not reimbursed) provided that the requirements listed in question 6.1 are respected. Following the ECJ judgment in Case C-316/09, INFARMED allows the disclosure on a website of information relating to prescription-only medicines, if such consists solely of the reproduction of administrative documents (i.e. package leaflet or the SmPC).

Information regarding a company's activities, research and business, as well as corporate and financial aspects, may also be disclosed.

**8.5 Are there specific rules, laws or guidance controlling the use of social media by companies?**

There are no specific rules regarding the use of social media by companies. Please refer to the answer to question 8.1 for the applicable rules.

## 9 Developments in Pharmaceutical Advertising

**9.1 What have been the significant developments in relation to the rules relating to pharmaceutical advertising in the last year?**

The most significant developments in relation to the rules relating to pharmaceutical advertising were the increase in the fines applicable to the infringement thereof.

**9.2 Are any significant developments in the field of pharmaceutical advertising expected in the next year?**

No significant developments in the field of pharmaceutical advertising are expected in the next year.

**9.3 Are there any general practice or enforcement trends that have become apparent in Portugal over the last year or so?**

There are no general practice or enforcement trends that have become noticeable in Portugal over the last year or so.

**Paulo Pinheiro**

Vieira de Almeida & Associados  
Av. Eng. Duarte Pacheco, 26  
1070-110 Lisbon  
Portugal

Tel: +351 21 311 3451  
Fax: +351 21 353 8939  
Email: [pp@vda.pt](mailto:pp@vda.pt)  
URL: [www.vda.pt](http://www.vda.pt)

**Education:** Law Degree, Faculty of Law, University of Lisbon, Portugal.

Post-graduation in European Legal Studies at the College of Europe in Bruges, Belgium.

Academic Assistance at the Faculty of Law, University of Lisbon, Portugal (1989-1991).

Assistant Professor at the "Instituto Superior de Gestão" (Business School) (1991-1998).

Paulo Pinheiro joined Vieira de Almeida & Associados in 1998. He is currently the partner in charge of the Public Law and Life Sciences areas of practice. In such capacity he has been involved in several transactions and projects in the following sectors: health; telecoms; energy and natural gas; transport; water; and waste. He has also been actively working in regulation and public procurement matters involving such sectors and establishing public-private partnerships.

Before joining VdA he worked as an associate at the law firm Botelho Moniz, Magalhães Cardoso & Ruiz (1989-1998).

He is the author of several articles in national and international publications.

Admitted to the Portuguese Bar Association as a specialist lawyer in administrative law.

**Practice areas:** Public Law and Life Sciences.

**Languages:** English, French and Spanish.

**Francisca Paulouro**

Vieira de Almeida & Associados  
Av. Eng. Duarte Pacheco, 26  
1070-110 Lisbon  
Portugal

Tel: +351 21 311 3451  
Fax: +351 21 353 8939  
Email: [fp@vda.pt](mailto:fp@vda.pt)  
URL: [www.vda.pt](http://www.vda.pt)

**Education:** Law Degree, Faculty of Law, University of Lisbon, Portugal.

Francisca Paulouro taught Pharmaceutical Law in the Master in Toxicology at the Faculty of Pharmacy, University of Oporto, in 2009, 2011, 2013 and 2015.

She joined VdA in 2002, and is currently Of Counsel of the Life Sciences practice area.

She has been active in various operations and projects in the health sector, particularly in the pharmaceutical sector, offering extensive experience in matters related with the regulation of this sector, mainly in pricing and reimbursement, marketing and promotional activities, distribution and contracts.

Before joining VdA she worked as an associate at the law firms Botelho Moniz, Nuno Ruiz & Associates and PMBGR – Pena, Machete, Botelho Moniz, Nobre Guedes, Ruiz & Associates.

Admitted to the Portuguese Bar Association.

**Practice areas:** Life Sciences.

**Languages:** English, French and Spanish.



Established in 1976, VdA has evolved from a small law firm set up by its founding partner, Vasco Vieira de Almeida, to a major independent law firm, presently including more than 170 lawyers devoted to excellence and innovation.

VdA advises both national and foreign clients from the public and private sectors, operating in a wide range of industries, including banking and finance, health, technology, telecommunications, tourism, infrastructure, energy and real estate.

The Life Sciences practice area is traditionally one of the areas with a high level of expertise. With a strong reputation amongst companies and regulatory authorities, the firm has a robust presence in the pharmaceutical industry, representing, on a regular and continuous basis, a large number of the most prominent pharmaceutical companies operating in Portugal. Members of the Life Sciences practice area have developed a very significant expertise and are continuously encouraged to expand their knowledge.

Through VdAtlas, the firm's international platform, VdA provides its clients with a professional network based on exclusive or preferential relations in the Portuguese speaking countries, Europe, South America and Asia, and in the world's main financial centres, bringing together highly specialised local support with a profound knowledge of clients' businesses.

*Pro bono* activity is developed with the same standards applied to clients' work, with VdA providing free legal assistance to charity institutions that work in the social, cultural and educational areas, as well as being the first major Portuguese law firm to create a *pro bono* and Corporate Social Responsibility programme.



## Other titles in the ICLG series include:

- Alternative Investment Funds
- Aviation Law
- Business Crime
- Cartels & Leniency
- Class & Group Actions
- Competition Litigation
- Construction & Engineering Law
- Copyright
- Corporate Governance
- Corporate Immigration
- Corporate Recovery & Insolvency
- Corporate Tax
- Data Protection
- Employment & Labour Law
- Environment & Climate Change Law
- Franchise
- Gambling
- Insurance & Reinsurance
- International Arbitration
- Lending & Secured Finance
- Litigation & Dispute Resolution
- Merger Control
- Mergers & Acquisitions
- Mining Law
- Oil & Gas Regulation
- Patents
- Private Client
- Private Equity
- Product Liability
- Project Finance
- Public Procurement
- Real Estate
- Securitisation
- Shipping Law
- Telecoms, Media & Internet
- Trade Marks



59 Tanner Street, London SE1 3PL, United Kingdom  
Tel: +44 20 7367 0720 / Fax: +44 20 7407 5255  
Email: [sales@glgroup.co.uk](mailto:sales@glgroup.co.uk)

[www.iclg.co.uk](http://www.iclg.co.uk)